Pseudocoloured electron micrograph showing malaria parasite (right, blue) attaching to a human red blood cell. .© NIAID

Dutch and US researchers have re-engineered non-druggable compounds that block the transmission and  metabolism of the malaria parasite Plasmodium falciparum.

Versantis' Management at EASL 2019 (from left:) Sophie Biguenet, CMO, Meriam Kabbaj, COO, and Vincent Forster, CEO © Versantis

Swiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.

Lundbeck CEO and President Deborah Dunsire. © Lundbeck A/S

Danish Lundbeck AS is has secured a stake in the  migraine market by paying US$1.95bn (€1.76bn) to acquire Alder BioPharmaceuticals Inc. 

© Autolus Therapeutics plc

Prague-based PPF Group has acquired a 19.2% stake in Autolus Therapeutics plc, a developer of T cell cancer therapies.

The Board of Directors of Menarini Group has appointed Mrs. Elcin Barker Ergun as CEO.

An oral squamous cancer cell (white) being attacked by two cytotoxic T cells (red), part of a natural immune response. © National Cancer Institute

German and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.

© Massachusetts General Hospital

French biotech Inotrem SA raised €39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.

© Ermium THerapeutics

Paris-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.
 

© Pharvaris NV

Leiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.

© Pixabay.com

London and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund.